TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01173237

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Use tracheal intubation for surfactant therapy
Description: Surfactant endotracheal administration after tracheal intubation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Use of Proseal laryngeal mask airway for surfactant therapy
Description: Surfactant use by proseal laryngeal mask airway
Study: NCT02433470

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation over the motor cortex

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation over the motor cortex
Study: NCT02264249

Intervention type: OTHER
Intervention: Esophagogastroduodenoscopy and colonoscopy split dose prep
Description: Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive the Split dose colonoscopy prep~split dose colonoscopy preparation- ½ evening before and ½ early AM (4L volume or 2L volume bowel preparation)

Intervention type: OTHER
Intervention: Esophagogastroduodenoscopy and colonoscopy Evening before colonoscopy prep
Description: Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive Evening before (4L, 2L or miralax bowel preparation)

Intervention type: OTHER
Intervention: Esophagogastroduodenoscopy and colonoscopy Same day prep colonoscopy preparation
Description: Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive Same day prep (4L volume or 2L volume or Miralax bowel preparation)
Study: NCT02773810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Family Planning Services
Description: Women who agree to enrollment will undergo our intervention, which will include an educational intervention and free on-site provision of all reversible contraceptive options, including LARC. This educational 5 intervention will be a one-on-one educational session on all available methods of contraception, with an emphasis on the safety and efficacy of long-acting reversible contraception (LARC) and the importance of planning a pregnancy in women with medical conditions requiring anticoagulation. A provider (clinic officer, nurse or physician) trained in family planning counseling and provision will provide all counseling and discussions in Kiswahili. Women will then be offered free, on-site provision of whichever contraceptive method they choose by a trained provider.
Study: NCT02831972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Study: NCT04494802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lower pressure
Description: During the operation, cuff pressure of LMA flexible is maintained to 30cmH2O

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: higher pressure
Description: During the operation, cuff pressure of LMA flexible is maintained to 50cmH2O
Study: NCT01424072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auriculotherapy by needles
Description: The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auriculotherapy by seeds
Description: We used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.The subjects were instructed to stimulate the points three times a day.
Study: NCT01193504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pred Forte
Description: Pred Forte BID for 4 weeks postop

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lotemax
Description: Lotemax BID for 4 weeks postop.
Study: NCT02876562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: root coverage with collagen matrix
Description: the material used is a porcine derived native collagen matrix which serves an alternative to connective tissue graft. the material is 1.5 mm in thickness with a specific tissue surface to allow for cell migration and a fibrous outer layer. it has a resorption time of 6 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: root coverage with collagen matrix
Description: the material used is a porcine derived native collagen matrix which serves an alternative to connective tissue graft. the material is 1.5 mm in thickness with a specific tissue surface to allow for cell migration and a fibrous outer layer. it has a resorption time of 6 months.
Study: NCT03009396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)
Description: For patients on ACTIVE or PLACEBO in the parent study (RHB-104-01), who were not in remission after 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)
Description: For patients on ACTIVE or PLACEBO in the parent study (RHB-104-01), who were not in remission after 26 weeks
Study: NCT02469311

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine impregnated cloths
Description: Pre-operative use of Chlorhexidine cloths night before and morning of surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine impregnated cloths
Description: Pre-operative use of Chlorhexidine cloths night before and morning of surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine impregnated cloths
Description: Pre-operative use of Chlorhexidine cloths night before and morning of surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine impregnated cloths
Description: Pre-operative use of Chlorhexidine cloths night before and morning of surgery

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard of care bathing with antibacterial soap and water
Description: Patients had standard pre-operative bathing with antibacterial soap and water the night before surgery.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard of care bathing with antibacterial soap and water
Description: Patients had standard pre-operative bathing with antibacterial soap and water the night before surgery.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard of care bathing with antibacterial soap and water
Description: Patients had standard pre-operative bathing with antibacterial soap and water the night before surgery.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard of care bathing with antibacterial soap and water
Description: Patients had standard pre-operative bathing with antibacterial soap and water the night before surgery.
Study: NCT03959176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine
Description: 2 drops administered once in the left eye in both study arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine
Description: 2 drops administered once in the left eye in both study arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropicamide
Description: 1 drop administered at two different times points in both eyes in both study arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropicamide
Description: 1 drop administered at two different times points in both eyes in both study arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine Ophthalmic Product
Description: 1 drop administered at two different time points in both eyes in both study arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine Ophthalmic Product
Description: 1 drop administered at two different time points in both eyes in both study arms
Study: NCT00357682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 80mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 80mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 300mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 300mg per day
Study: NCT02970942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Once daily administration of semaglutide subcutaneously (s.c., under the skin) in three different doses (0.1 mg, 0.2 mg and 0.4 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Once daily administration of semaglutide subcutaneously (s.c., under the skin) in three different doses (0.1 mg, 0.2 mg and 0.4 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Once daily administration of semaglutide subcutaneously (s.c., under the skin) in three different doses (0.1 mg, 0.2 mg and 0.4 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily administration subcutaneously ( s.c., under the skin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily administration subcutaneously ( s.c., under the skin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily administration subcutaneously ( s.c., under the skin)
Study: NCT04462627

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood group determination
Description: Determination of the blood group (ABO/LE)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood group determination
Description: Determination of the blood group (ABO/LE)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood group determination
Description: Determination of the blood group (ABO/LE)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Antibody titration
Description: Natural anti-A and anti-B antibody levels will be determined by a gel agglutination technique on the Biorad IH-500 automaton.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Antibody titration
Description: Natural anti-A and anti-B antibody levels will be determined by a gel agglutination technique on the Biorad IH-500 automaton.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Antibody titration
Description: Natural anti-A and anti-B antibody levels will be determined by a gel agglutination technique on the Biorad IH-500 automaton.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Administration of a probiotic to healthy volunteers to determine if it increases the level of circulating natural anti-A and anti-B antibodies (Probactiol Plus (Metagenics)).
Study: NCT04106752

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Provide caffeine supplements with or without meal before exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Provide caffeine supplements with or without meal before exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Provide caffeine supplements with or without meal before exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Provide caffeine supplements with or without meal before exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Provide caffeine supplements with or without meal before exercise
Study: NCT00689858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol, Ginkgo biloba and placebo
Description: dosing time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol, Ginkgo biloba and placebo
Description: dosing time
Study: NCT04199988

Intervention type: DIAGNOSTIC_TEST
Intervention: Posterior Shoulder Endurance Test
Description: Isometric posterior shoulder endurance test: In the prone position, the athlete's shoulder will be placed at horizontal abduction, and the time for maintaining this position will be recorded.~Isotonic shoulder endurance test: In the prone position, the athlete's shoulder will be placed at horizontal abduction and asked to perform horizontal adduction-abduction, and the athlete will horizontally abducted-adducted his/her arm to 90 degrees at a cadence of 30 beats per minute. The number of repetitions will be recorded.

Intervention type: DIAGNOSTIC_TEST
Intervention: Posterior Shoulder Endurance Test
Description: Isometric posterior shoulder endurance test: In the prone position, the athlete's shoulder will be placed at horizontal abduction, and the time for maintaining this position will be recorded.~Isotonic shoulder endurance test: In the prone position, the athlete's shoulder will be placed at horizontal abduction and asked to perform horizontal adduction-abduction, and the athlete will horizontally abducted-adducted his/her arm to 90 degrees at a cadence of 30 beats per minute. The number of repetitions will be recorded.
Study: NCT02425852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Azathioprine alone versus Azathioprine and IFX

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Azathioprine alone versus Azathioprine and IFX

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Study: NCT03859310

Intervention type: DEVICE
Intervention: SD-OCT
Description: Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures

Intervention type: DEVICE
Intervention: SD-OCT
Description: Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures

Intervention type: DEVICE
Intervention: SD-OCT
Description: Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures

Intervention type: DEVICE
Intervention: SD-OCT
Description: Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
Study: NCT03475836

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mentha piperita
Description: Commercially available essential oil suspended in an off-the-shelf vegetable oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mentha piperita
Description: Commercially available essential oil suspended in an off-the-shelf vegetable oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert placebo control in the form of vegetable oil. This matches the vegetable oil in the active intervention condition.
Study: NCT01962740

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stent implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stent implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stent implantation
Study: NCT01931293

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation of vitamin B complex, C, B12, folic acid, Iron and Zinic
Description: Vitamin Supplement therapy
Study: NCT01771224

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palmitoleic acid
Description: Palmitoleic acid and 5-ASA
Study: NCT05188833

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Transcranial Magnetic Stimulation
Description: Deep TMS, unlike traditional TMS, is a treatment method that provides stimulation of lower parts of the brain and larger brain volume, in addition to drug treatment and psychotherapy approaches, in addition to localized brain regions magnetic stimulation is a treatment method where disease symptoms are addressed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Transcranial Magnetic Stimulation
Description: Deep TMS, unlike traditional TMS, is a treatment method that provides stimulation of lower parts of the brain and larger brain volume, in addition to drug treatment and psychotherapy approaches, in addition to localized brain regions magnetic stimulation is a treatment method where disease symptoms are addressed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Paroxetine is a type of antidepressant known as an SSRI (selective serotonin reuptake inhibitor). It's often used to treat depression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Paroxetine is a type of antidepressant known as an SSRI (selective serotonin reuptake inhibitor). It's often used to treat depression.
Study: NCT03240549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: The patients in conventional group continued the previous chemotherapy,and the patients in experimental group received adding bevacizumab to previous chemotherapy regimen.
Study: NCT02392819

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Panax ginseng
Description: Pananx ginseng is provided prior to a standardised breakfast, effects on test variables are determined at fasting and repeatedly postprandially the breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00915382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1 and cisplatin
Description: S-1: 80 mg/m2/day po on Days 1-14~cisplatin: 60 mg/m2 iv on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1 and cisplatin
Description: S-1: 80 mg/day with BSA less than 1.25 m2, 100 mg/day with BSA more than 1.25 m2 and less than 1.5 m2, 120 mg/day with BSA more than 1.5 m2 on Days 1-21 and~cisplatin: 60 mg/m2 iv on Day 1 or 8
Study: NCT01570946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification
Description: The mobile phone based intervention will use short messaging service (SMS or text messaging) to deliver education, treatment targets, advice, support and motivation.
Study: NCT04625504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Intervention
Description: Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
Study: NCT00473239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol.
Description: 100,000 IU of Vitamin D
Study: NCT03527459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPARC B
Description: SPARC B includes all aspects of the SPARC A clinical program, as well as targeting negative cognitions of perceived burdensomeness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SPARC A
Description: SPARC A is an existing clinical program with a general focus on negative cognitions.
Study: NCT00364104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadruple sequential Helicobacter pylori eradication + iron sulfate
Description: A 10-day course of Hp infection sequential eradication therapy plus 6-weeks of iron supplementation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadruple sequential Helicobacter pylori eradication therapy
Description: A 10-day course of Hp infection sequential eradication therapy only plus 6-weeks of matching placebo of iron supplementation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: 6-weeks of iron supplementation only plus 10-days matching placebo of Hp infection eradication therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo only (10-days of matching placebo of Hp eradication therapy and 6-weeks of matching iron supplementation).
Study: NCT04626908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC022F CAR-T cells
Description: Each subject receive GC022F CAR-T cells by intravenous infusion
Study: NCT01608945

Intervention type: DRUG
Intervention: Hydrocortisone sodium succinate
Description: 100mg/day
Study: NCT02442388

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Instrumentation technique with hand file
Description: type of instrumentation technique for root canal treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Instrumentation technique with ProTaper
Description: type of instrumentation technique for root canal treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Instrumentation technique with WaveOne
Description: type of instrumentation technique for root canal treatment
Study: NCT03674905

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intra-articular injection
Description: Intra-articular injection at the completion of TAA procedure.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Peripheral nerve block
Description: Pre-operative peripheral nerve block.
Study: NCT01150188

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino acids
Description: 11 g amino acids two times per day for eight weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of inert compounds, 11 g two times per day for eight weeks
Study: NCT04113421

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast-enhanced chest CT
Description: A single follow-up contrast-enhanced chest CT to compare off-line with the contrast-enhanced chest CT done at baseline for the diagnosis of PE.
Study: NCT01872390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination Intervention Package
Description: CIP will contain programmatic, structural and psychosocial components including: 1) nurse training and mentorship in TB/HIV cotreatment using a clinical algorithm; 2) reimbursement of transportation costs to monthly clinic visits for patients and treatment supporters; 3) health education using a TB and HIV treatment literacy curriculum for patients and treatment supporters; and 4) real-time adherence support using short message service (SMS) text messaging and trained village health workers (VHW). These components were selected for their promise, practicality, and feasibility of implementation and scale-up in HIV programs in diverse settings - in addition to SOC.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Usual procedures for management of HIV-infected TB patients will be followed: Three I's training, ART provision to TB patients in integrated clinics, and treatment supporter for TB treatment.
Study: NCT00781703

Intervention type: OTHER
Group type: OTHER
Intervention: DIAMOND depression care model
Description: Patients in activated clinic sites will receive the DIAMOND depression care model, including a care manager, frequent use of the PHQ9, treatment adjustment as indicated, psychiatric consultation, relapse prevention.